Gilde Healthcare Cooperatieve Sells 49,869 Shares of LAVA Therapeutics (NASDAQ:LVTX) Stock

LAVA Therapeutics N.V. (NASDAQ:LVTX) major shareholder Gilde Healthcare Cooperatieve sold 49,869 shares of the business’s stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $1.55, for a total value of $77,296.95. Following the completion of the sale, the insider directly owned 5,294,178 shares in the company, valued at approximately $8,205,975.90. The trade was a 0.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Gilde Healthcare Cooperatieve also recently made the following trade(s):

• On Thursday, October 9th, Gilde Healthcare Cooperatieve sold 48,169 shares of LAVA Therapeutics stock. The shares were sold at an average price of $1.56, for a total value of $75,143.64.
• On Wednesday, October 8th, Gilde Healthcare Cooperatieve sold 28,954 shares of LAVA Therapeutics stock. The shares were sold at an average price of $1.57, for a total value of $45,457.78.

LAVA Therapeutics Stock Down 0.6%

Shares of NASDAQ LVTX opened at $1.55 on Friday. The firm has a market cap of $40.78 million, a price-to-earnings ratio of -1.48 and a beta of 0.50. LAVA Therapeutics N.V. has a 52-week low of $0.85 and a 52-week high of $2.09. The business’s 50 day moving average is $1.55 and its two-hundred day moving average is $1.39.

LAVA Therapeutics (NASDAQ:LVTX) last announced its earnings results on Wednesday, August 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). Analysts anticipate that LAVA Therapeutics N.V. will post -1.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

LVTX has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of LAVA Therapeutics in a research report on Wednesday. Jefferies Financial Group lowered LAVA Therapeutics from a “buy” rating to a “hold” rating and cut their price objective for the stock from $3.00 to $1.50 in a research report on Tuesday, August 5th. Finally, HC Wainwright cut their price objective on LAVA Therapeutics from $1.50 to $1.24 and set a “neutral” rating on the stock in a research report on Tuesday, August 5th. Six equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $2.69.

Institutional Investors Weigh In On LAVA Therapeutics

Several hedge funds have recently made changes to their positions in the business. Lepercq De Neuflize Asset Management LLC raised its holdings in LAVA Therapeutics by 34.8% during the second quarter. Lepercq De Neuflize Asset Management LLC now owns 31,000 shares of the company’s stock worth $41,000 after purchasing an additional 8,000 shares in the last quarter. BML Capital Management LLC raised its holdings in LAVA Therapeutics by 0.5% during the second quarter. BML Capital Management LLC now owns 1,970,610 shares of the company’s stock worth $2,601,000 after purchasing an additional 10,000 shares in the last quarter. XTX Topco Ltd purchased a new position in LAVA Therapeutics during the first quarter worth about $31,000. Finally, Rangeley Capital LLC purchased a new position in LAVA Therapeutics during the second quarter worth about $36,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.